AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04973956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
Study NCT04973956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention
Study NCT04921033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EEN (Nestle Modulen®)
Description: 35kcal/kg/day for every patient
Study NCT04921033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standart of care
Description: * Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Study NCT05636878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Intervention Team in Perinatal Psychiatry (EMPPer)
Description: The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
Study NCT05788042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro TMS device (ARTG: 204659)
Description: rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
Study NCT05788042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro TMS device (ARTG: 204659)
Description: rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
Study NCT05788042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)
Description: tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
Study NCT05788042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)
Description: tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
Study NCT05152342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Awareness Training for Legal System Staff
Description: Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
Study NCT05152342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for self-stigma
Description: Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
Study NCT05635825 — intervention group
Intervention type: OTHER
Intervention: Observational Survey
Description: Collection of a 4-day food record
Study NCT06066619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Cranberry Juice
Description: 100% Cranberry juice will be provided from Ocean Spray Company.
Study NCT06066619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Cranberry Juice + 200 mg L-theanine
Description: 100% Cranberry Juice + 200 mg L-theanine will be provided from Ocean Spray Company.
Study NCT06066619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry juice.
Study NCT04999878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
Description: All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype.
Study NCT05895136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01
Study NCT05895136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
Study NCT05895136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: SMT will be considered non-study medication and is not specified in the protocol.
Study NCT06362512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: participants receive three 60-minute COGMOTION dual-task exercise sessions per week for six consecutive weeks.
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 0.1g bid
Study NCT05018923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: 0.5g qid
Study NCT05218343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR-based nudge interventions
Description: Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
Study NCT05553457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing of MyHand-SCI Device
Description: Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
Study NCT06015074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
Study NCT06015074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
Study NCT06238687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
Study NCT06362512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-task training
Description: participants receive 30-minute single motor tasks with 30-minute single cognitive tasks three times per week for six consecutive weeks.The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately.
Study NCT06362512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb strengthening exercise
Description: participants receive upper limb strengthening exercise for 30 minutes and flexibility exercises for 30 minutes three times per week for six consecutive weeks. The training is performed in sitting or standing position and no cognitive load will be added.
Study NCT04895865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RPE-based load and repetition number selection
Description: Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise
Study NCT04895865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Predetermined load and number of repetitions
Description: Trainees predetermine the load and perform ten repetitions per set and exercise
Study NCT05362565 — intervention group
Intervention type: BIOLOGICAL
Intervention: Salivary Sampling
Description: The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit
Study NCT06156423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Description: Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
Study NCT06156423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise
Description: The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
Study NCT04987762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adhansia XR
Description: Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
Study NCT05684627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fast mimicking diet group
Description: Test group will be assigned to follow one cycle of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 5 visits.
Study NCT05684627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal diet group
Description: Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 5 visits.
Study NCT04936074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle preserving selective laminectomy
Description: Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
Study NCT04936074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy with instrumented fusion
Description: A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
Study NCT05540912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference
Study NCT05540912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1
Study NCT05540912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2
Study NCT05756816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurePulse VSP
Description: A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VSP placed on the volunteer.
Study NCT05756816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurePulse VS
Description: A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VS placed on the volunteer.
Study NCT04822792 — intervention group
Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test
Study NCT03400306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, capsule
Description: capsule; 50 mg or 100 mg
Study NCT03400306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, tablet
Description: tablet; 400 mg
Study NCT03400306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study NCT03400306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous
Study NCT05244278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic-GI genius (CADe system for detecting colorectal polyps)
Description: Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
Study NCT05314036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized test meal
Description: During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
Study NCT06180304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
Study NCT06233045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-Test product
Description: Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
Study NCT06233045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-Reference product
Description: Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
Study NCT05608850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Then Stretch
Description: This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
Study NCT05608850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretch Then Exercise
Description: This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
Study NCT05802368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality group
Description: a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
Study NCT05802368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
Study NCT05085626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparib+chidamide
Description: Arms A will be treated with fluzoparib in combination with cedaramide
Study NCT05085626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparib+camrelizumab
Description: Arms B will be treated with fluzoparib in combination with camrelizumab
Study NCT05012800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine
Description: Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
Study NCT06218225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: 1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout
Study NCT06218225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
Study NCT06186141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
Study NCT06186141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
Study NCT06517667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icross tear substitute
Description: Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
Study NCT06051097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sleep study
Description: over-night polysomnography
Study NCT06517667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyabak tear substitute
Description: Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
Study NCT05815654 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Warm Palace Analgesic Point Sticker
Description: The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
Study NCT05815654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm Palace Analgesic Point Sticker
Description: The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
Study NCT05804045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimicotinib(ABSK021)
Description: capsule
Study NCT05804045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib(ABSK021)
Description: capsule
Study NCT05804045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule